266 related articles for article (PubMed ID: 30898327)
1. Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore.
Falade-Nwulia O; Irvin R; Merkow A; Sulkowski M; Niculescu A; Olsen Y; Stoller K; Thomas DL; Latkin C; Mehta SH
J Subst Abuse Treat; 2019 May; 100():45-51. PubMed ID: 30898327
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.
Patel EU; Solomon SS; Mcfall AM; Srikrishnan AK; Pradeep A; Nandagopal P; Laeyendecker O; Tobian AAR; Thomas DL; Sulkowski MS; Kumar MS; Mehta SH
Int J Drug Policy; 2018 Jul; 57():51-60. PubMed ID: 29679811
[TBL] [Abstract][Full Text] [Related]
3. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington.
Corcorran MA; Tsui JI; Scott JD; Dombrowski JC; Glick SN
Drug Alcohol Depend; 2021 Mar; 220():108525. PubMed ID: 33461152
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era.
Falade-Nwulia O; Gicquelais RE; Astemborski J; McCormick SD; Kirk G; Sulkowski M; Thomas DL; Mehta SH
Liver Int; 2020 Oct; 40(10):2407-2416. PubMed ID: 32770638
[TBL] [Abstract][Full Text] [Related]
5. Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial.
Solomon SS; Quinn TC; Solomon S; McFall AM; Srikrishnan AK; Verma V; Kumar MS; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Thomas DL; Sachdeva KS; Lucas GM; Mehta SH
J Hepatol; 2020 Jan; 72(1):67-74. PubMed ID: 31604081
[TBL] [Abstract][Full Text] [Related]
6. High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011-2014: missed opportunities for hepatitis C testing.
Enkelmann J; Gassowski M; Nielsen S; Wenz B; Roß S; Marcus U; Bremer V; Zimmermann R;
Harm Reduct J; 2020 Jan; 17(1):7. PubMed ID: 31924208
[TBL] [Abstract][Full Text] [Related]
7. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
8. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
[TBL] [Abstract][Full Text] [Related]
9. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
[TBL] [Abstract][Full Text] [Related]
10. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
[TBL] [Abstract][Full Text] [Related]
11. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.
Socías ME; Ti L; Wood E; Nosova E; Hull M; Hayashi K; Debeck K; Milloy MJ
Liver Int; 2019 Aug; 39(8):1400-1407. PubMed ID: 30653809
[TBL] [Abstract][Full Text] [Related]
12. Individual and network factors associated with HCV treatment uptake among people who inject drugs.
Falade-Nwulia O; Sacamano P; McCormick SD; Yang C; Kirk G; Thomas D; Sulkowski M; Latkin C; Mehta SH
Int J Drug Policy; 2020 Apr; 78():102714. PubMed ID: 32135398
[TBL] [Abstract][Full Text] [Related]
13. Correlates of anti-hepatitis C positivity and use of harm reduction services among people who inject drugs in two cities in Croatia.
Handanagic S; Sevic S; Barbaric J; Dominkovic Z; Dakovic Rode O; Begovac J; Bozicevic I
Drug Alcohol Depend; 2017 Feb; 171():132-139. PubMed ID: 28088084
[TBL] [Abstract][Full Text] [Related]
14. Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals.
Coyle CR; Gicquelais RE; Genberg BL; Astemborski J; Falade-Nwulia O; Kirk GD; Thomas DL; Mehta SH
Drug Alcohol Depend; 2023 Dec; 253():. PubMed ID: 38456165
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with phylogenetic clustering of hepatitis C among people who inject drugs in Baltimore.
Falade-Nwulia O; Hackman J; Mehta SH; McCormick SD; Kirk GD; Sulkowski M; Thomas D; Latkin C; Laeyendecker O; Ray SC
BMC Infect Dis; 2020 Nov; 20(1):815. PubMed ID: 33167892
[TBL] [Abstract][Full Text] [Related]
16. 'Hep C's like the common cold': understanding barriers along the HCV care continuum among young people who inject drugs.
Skeer MR; Ladin K; Wilkins LE; Landy DM; Stopka TJ
Drug Alcohol Depend; 2018 Sep; 190():246-254. PubMed ID: 30071457
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: Protective effects of non-injecting drug use.
Des Jarlais DC; Arasteh K; Feelemyer J; McKnight C; Barnes DM; Perlman DC; Uuskula A; Cooper HLF; Tross S
Drug Alcohol Depend; 2018 Nov; 192():74-79. PubMed ID: 30243142
[TBL] [Abstract][Full Text] [Related]
18. On the way to Hepatitis C elimination in the Republic of Georgia-Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study.
Chikovani I; Ompad DC; Uchaneishvili M; Sulaberidze L; Sikharulidze K; Hagan H; Van Devanter NL
PLoS One; 2019; 14(4):e0216123. PubMed ID: 31034530
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
[TBL] [Abstract][Full Text] [Related]
20. Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study).
Barré T; Marcellin F; Di Beo V; Delorme J; Rojas Rojas T; Mathurin P; Protopopescu C; Bailly F; Coste M; Authier N; Carrieri MP; Rolland B
Addiction; 2020 Mar; 115(3):573-582. PubMed ID: 31595554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
